VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds

Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
You are here : IndiaNotes >> Research & Analysis >> Industries >> Pharmaceuticals and health care >> Research

Pharma: Drug pricing policy finanlized, sent for Cabinet approval

IndiaNivesh | 22 Nov, 2012  | Follow Author | Add to my Favourites 
  • Rate this article
    (Average Rating 0.0 Based on 0 ratings)

GOM finalized Pharma Pricing Policy and sent for Cabinet approval:

The Group of Ministers(GOM) has finalized the drug pricing policy, which is aimed to control the price of 348 essential medicines. According to GOM Chairman, Cabinet now will consider the policy before Supreme Court’s deadline( 27 November 2012) to finalize the matter.

Details of the final policy are not clear yet but it appears that GOM has not considered Cost Based mechanism, as advocated by Supreme Court. This would be sentiment positive for the industry as a whole. Among the domestic pharma companies, Cipla, Cadila, Ranbaxy, Alembic Pharma & Torrent and among the MNCs GSK & Pfizer would be biggest beneficiary.

However final outcome & impact of that on industry will be known only once details of policy are known. Though, industry can take a positive clue that it is not cost based mechanism, which was expected to impact industry more negatively.

  Read full report Click here to read the full report

About IndiaNivesh
IndiaNivesh as a financial group, provide a wide range of services that includes Stressed Asset Management, Investment Banking, Securities Broking, Commodities and Currency Broking, Insurance Broking, Depository Services, Wealth Management and various other financial products.

For more information please write in to [email protected]

Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor accept any liability whatsoever arising from the use of any of the above contents.

Technical Calls

What are technical calls?

Other Articles

Have a question?